NeoStem, Inc. (NBS) Announces Publication of Embryonic-Like Stem Cell Research

NeoStem, in a collaborative publication with the University of Michigan School of Dentistry, announced that data further expands the therapeutic potential of its proprietary regenerative cell therapy product, “VSELSTM” (very small embryonic-like stem cells), by demonstrating bone regeneration capabilities. The paper concerns human VSEL stem cells and how cells form human bone when implanted in bone tissue of SCID mice. The study was published online ahead of print in the journal Stem Cells and Development.

This published controlled study was funded by NIH and led by Dr. Russell Taichman, Major Ash Collegiate Professor and Co-Director of the Scholars Program in Dental Leadership Department of Periodontics & Oral Medicine, University of Michigan and Dr. Aaron Havens, Department of Orthodontics and Pediatric Dentistry at University of Michigan. The study involved isolating G-CSF mobilized VSEL stem cells from the blood of healthy donors and transplanting them into burr holes made in the cranial bones of SCID mice.

VSELs are a population of stem cells found in adult bone marrow with potential regenerative properties similar to those of embryonic stem cells. After three months, it was observed that the implanted VSEL stem cells had differentiated into human bone tissue in the crania of the mice. NeoStem demonstrated that these cells can be mobilized into the peripheral blood, enabling a minimally invasive means for collecting what NeoStem believes to be a population of stem cells that have the potential to achieve the positive benefits associated with embryonic stem cells. This new procedure mitigates the risk of ethical or moral dilemmas and the potential negative effects known to be associated with embryonic stem cells.

Dr. Taichman stated, “I believe this work represents a true partnership between Industry and Academic Institutions. Our findings that VSEL cells can generate human bone in animals would not have been feasible without the help and vision that Dr. Denis Rodgerson and his team at NeoStem brought to the table. It was my privilege to have been a part of this collaborative effort, and I see the resulting data as a significant milestone in stem cell therapy development. It is truly inspiring.”

Dr. Robin Smith, Chairman and CEO of NeoStem, added, “This is very exciting data that we believe will be the foundation for future VSEL stem cell studies of bone regeneration in humans. We look forward to moving the development work from the laboratory into the clinic to develop a therapeutic stem cell product to enhance bone formation in humans.”

NeoStem is an emerging leader in the fast growing cell therapy market. They continue to develop and build on core capabilities in cell therapy. The company believes that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. As an emerging technology and market leading company in this fast developing cell therapy market, their multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC (“PCT”), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities.

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html